![]()
Analysts upwardly revised their ratings on Cardinal Health Inc (CAH), Whole Foods Market, Inc. (WFM), and Cirrus Logic, Inc. (CRUS)
Analysts are weighing in today on healthcare services provider Cardinal Health Inc (NYSE:CAH), healthy grocer Whole Foods Market, Inc. (NASDAQ:WFM), and Apple Inc. (NASDAQ:AAPL) supplier Cirrus Logic, Inc. (NASDAQ:CRUS). Here's a quick roundup of today's bullish brokerage notes on CAH, WFM, and CRUS.
- CAH is in the spotlight this morning, after the firm agreed to buy Johnson & Johnson's (NYSE:JNJ) heart-product unit (subscription required) for $1.94 billion in cash. In addition, Mizuho Securities lifted its price target on Cardinal Health Inc to $103 from $93 -- in uncharted territory for CAH -- and reiterated its "buy" endorsement. On the charts, CAH touched a record high of $89.43 just last week, and has added 1.4% to flirt with $89.20 today. Most analysts are already on the bullish bandwagon, as the security boasts 11 "buy" or better ratings, compared to three lukewarm "holds" and not a single "sell." Still, more price-target hikes could ensue, as the consensus 12-month price target of $92.62 is just a stone's throw from CAH's current perch.
- WFM earned a trio of upbeat analyst notes this morning, sending the shares 0.3% higher to $56.63. J.P. Morgan Securities, BMO, and SunTrust Robinson all lifted their price targets, to $56, $58, and $67, respectively. While the latter offered up a "buy" rating, the former underscored the equivalent of "neutral" ratings. The shares of Whole Foods Market, Inc. have added 12% so far in 2015, and touched a fresh annual high of $57.57 on Feb. 19. However, analysts are split on WFM, with 12 doling out "hold" or worse ratings, compared to 11 "buy" or better endorsements.
- Finally, Barclays hiked its price target on CRUS to $35, and reiterated an "overweight" rating. The equity has been on fire in 2015, gaining 31.1%, and touched a two-year peak of $30.92 out of the gate today. More price-target boosts could be in store, should CRUS extend its upward momentum. The average 12-month price target of $33.75 sits just 12.1% north of the stock's current perch at $30.11.